Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis

Journal of Korean Medical Science

Volumn 23, Issue 2, 2008, Pages 320-323

  Park, Soo Jeong ^a,b   Han, Chi Wha ^a  

^a The Catholic University of Korea   (South Korea)

^b Our Lady of Mercy Hospital   (South Korea)

Author keywords

Aplastic anemia; Deferoxamine; Hemochromatosis

Indexed keywords

DEFEROXAMINE; IRON; IRON CHELATING AGENT;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; CASE REPORT; CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; HEMOCHROMATOSIS; HUMAN; IMMUNE SYSTEM; MALE; METHODOLOGY; PATHOLOGY; THORAX RADIOGRAPHY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, APLASTIC; CHELATION THERAPY; DEFEROXAMINE; ERYTHROCYTE TRANSFUSION; HEMOCHROMATOSIS; HUMANS; IMMUNE SYSTEM; IRON; IRON CHELATING AGENTS; MALE; RADIOGRAPHY, THORACIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 43449119849     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.2.320     Document Type: Article

References (14)

1. Keohane EM. Acquired aplastic anemia. Clin Lab Sci 2004; 17: 165-71.
2. Geissler K. Pathophysiology and treatment of aplastic anemia. Wien Klin Wochenschr 2003; 115: 444-50.
3. Maciejewski JP, Risitano AM. Aplastic anemia: management of adult patients. Hematolgoy Am Soc Hematol Educ 2005; 110-7.
4. Mwanda OW, Otieno CF, Abdalla FK. Transfusion haemosiderosis inspite of regular use of desferrioxamine: case report. East Afr Med J 2004; 81: 326-8.
5. Girot R, Thevenin M, Bouveret JP, Jeannel F, Rymer JC. Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine. Arch Fr Pediatr 1980; 37: 241-7.
6. Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 1989; 115: 151-5.
7. Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, Park CJ, Lee KH. Spontaneous remission of aplastic anemia: a retrospective analysis. Haematologica 2001; 86: 928-33.
8. Carotenuto P, Pontesilli O, Cambier JC, Hayward AR. Desferoxamine blocks IL 2 receptor expression on human T lymphocytes. J Immunol 1986; 136: 2342-7.
9. Hoffbrand AV, Ganeshaguru K, Hooton JW, Tattersall MH. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976; 33: 517-26.
10. Shao Z, Chu Y, Zhang Y, Chen G, Zheng Y. Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin. Am J Hematol 1998; 59: 185-91.
11. Bessho M, Hirashima K, Asano S, Ikeda Y, Ogawa N, Tomonaga M, Toyama K, Nakahata T, Nomura T, Mizoguchi H, Yoshida Y, Niitsu Y, Kohgo Y. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group. Eur J Haematol 1997; 58: 265-72.
12. Aucella F, Vigilante M, Scalzulli P, Musto P, Prencipe M, Valente GL, Carotenuto M, Stallone C. Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1171-5.
13. Kling PJ, Dragsten PR, Roberts RA, Dos Santos B, Brooks DJ, Hedlund BE, Taetle R. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol 1996; 95: 241-8.
14. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005; 74: 84-5.